KalshiCheck availabilityKYC requiredVerified resolution dataWell calibratedSelected book midpoint
Before 2028 · —
Loading selected book…
—
Stored price
Before 2028 91%Leader of 3 outcomes
Before 2028 91%Market quality
41 / 100
Low quality24h Volume
—
Open interest
$3.4K
Medium open interestBid / Ask
— / —
Before 2028Spread
—
Market data
Updated 46 minutes ago
LaggingMar 24, 26, 2:00 PM UTCJul 1, 27, 3:59 AM UTC
Chart and changes show stored historical probabilities, not the selected live book.
Trends
Selected row: book midpoint. Other rows: stored references, possibly normalized; 24h changes use stored history.
Venue terms
Source: Kalshi
Informational venue terms only; CoinRithm paper trading uses its own rules.
- Early close:
- Yes
- Settlement timer:
- 30m (informational)
Market depth · Before 2028
Loading selected book…
—
Related Markets
Related questions for context, not a comparison of equivalent contracts.
Will the FDA approve CagriSema?
KalshiWill the FDA approve any psychedelic substance for medical use this year?
KalshiWill the FDA approve retatrutide?
KalshiWhen will the FDA approve Compass Pathways' COMP360 Psilocybin?
KalshiWill FDA approve any mRNA vaccine against melanoma before 2028?
Manifold MarketsWill FDA approve any mRNA vaccine against any type of herpes simplex infection before 2028?
Manifold MarketsRules
If the FDA approves Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema for marketing before Jan 1, 2028, then the market resolves to Yes.
Rules for each outcome
- Before 2028
- If the FDA approves Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema for marketing before Jan 1, 2028, then the market resolves to Yes.
- Before July 2027
- If the FDA approves Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema for marketing before Jul 1, 2027, then the market resolves to Yes.
- Before October 2027
- If the FDA approves Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema for marketing before Oct 1, 2027, then the market resolves to Yes.
